Program
LY4298445
A development code.
Its studies are mostly in Lupus Erythematosus, Systemic, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 11 open or running | phase 1since Dec 1, 2025 | Dec 1, 2025 | Mar 2028phase 1 · NCT07276958 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2025First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT07276958 · 68 planned · Australia, China, Japan
Ahead
- Mar 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07276958
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07276958Lupus Erythematosus, Systemic · Australia, China, Japan | 1 | Recruiting | Mar 2028 | 68 |
How it is read
Names in the registry
- “LY4298445”, 2 entries
Codes read as this program: LY4298445.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.